Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)

Trials by Status

completed250%
recruiting125%
unknown125%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_2

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

NCT04570332
recruiting

A Clinico-biological Database of Lung Cancers

NCT03387865
unknownphase_1

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

NCT05265650
completednot_applicable

Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)

NCT03322319

Clinical Trials (4)

Showing 4 of 4 trials
NCT04570332Phase 2

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

Completed
NCT03387865

A Clinico-biological Database of Lung Cancers

Recruiting
NCT05265650Phase 1

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

Unknown
NCT03322319Not Applicable

Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)

Completed

All 4 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
4